%201.jpg)
The science behind transformation
For many people, antidepressants, antianxiety and talk therapy approaches haven’t been enough. Ketamine works on a different system in the brain—the glutamate system—creating a rapid shift in mood for a significant number of people with treatment-resistant depression, anxiety, and related conditions, often within hours to days instead of weeks. (Nature)
Ketamine opens a window of neuroplasticity—a period when the brain is more able to form new connections and loosen rigid patterns. This plastic state can function like a temporary “critical period”of learning similar to those seen in early development, when the brain becomes uniquely responsive to experience and emotional learning. When this window is coupled with clear guidance in a structured program—careful medical oversight and integration support—therapy, behavior changes, and daily-life adjustments have a better chance to take root. (PMC)
Your safety is our responsibility
Ketamine isn't new. It's a long-established medication that has been used in hospitals for decades, backed by extensive research describing how it works in the body and how clinicians use it safely and effectively.
In mental health, the evidence base has grown substantially—especially for treatment-resistant depression—and the FDA has authorized a ketamine-based antidepressant (esketamine), signaling that this mechanism is not experimental, but a recognized medical pathway when delivered with clear protocols and oversight.
What makes it safe for most people.
Safety is determined before and around dosing: careful screening and medication review, conservative dosing and clear limits on frequency, and structured monitoring with follow-up so each session is part of a guided process rather than a one-off event.
Why psychiatric ketamine is taken seriously.
The clinical model is no longer fringe. Ketamine is widely considered the most significant breakthrough in depression research in 50 years, and FDA-approved esketamine comes with mandatory monitoring and clear protocols, reinforcing that supervision and structure are part of its efficacy.
What most people notice during a session.
Low-dose ketamine has a predictable, time-limited arc: changes in perception and dissociation can occur, and blood pressure or heart rate may rise temporarily, with effects typically peaking during the session and resolving as the medicine wears off.
When it’s not the right choice.
Ketamine isn’t a fit for everyone, especially when certain cardiovascular risks are uncontrolled, when there’s active psychosis or mania, when there is active bipolar mania, or when substance misuse risk is high. Sometimes the right next step is a different modality or a higher level of care.
How does ketamine work?
Ketamine doesn’t just change how you feel—it changes what your brain is able to do for a period of time. Here’s how it differs from a standard psychiatric approach, why it can work quickly, and what the neuroplastic window makes possible.
A different target than standard antidepressants.
Most traditional antidepressants work on serotonin and can take 6-12 weeks to reach full effect. Ketamine primarily blocks NMDA-type glutamate receptors on inhibitory neurons, briefly increasing glutamate and activating AMPA receptors, which can lead to a cascade that supports synapse growth and circuit repair in mood-related areas of the brain. (PMC)
Opening a neuroplastic window.
Studies show that ketamine increases brain-derived neurotrophic factor (BDNF) and activates pathways like mTOR, which support synaptogenesis and stronger communication between brain regions involved in mood, motivation, and reward. This neuroplastic window appears to peak in the first couple of days after treatment. During this time, the brain is more open to learning, allowing for new emotional patterns, insights, and relational experiences to become more deeply encoded. This is why what you do with this window—therapy, relationship care, sleep, movement—matters so much. (PMC)
A rapid shift in mood and suicidal thinking.
In clinical trials, a single low-dose ketamine infusion has improved depressive symptoms within 24 hours for many people with treatment-resistant depression, with benefits sometimes lasting days to weeks; repeated treatments can extend that effect. Ketamine has also been shown to reduce suicidal ideation quickly, which is why it’s being studied and used in some acute-care settings as an option when waiting weeks isn’t safe. (PMC)
How ketamine fits into this 90-day process
Medicine plus process, not medicine alone.
We use ketamine as one part of a 90-day process that includes psychiatric care, music-assisted sessions, integration therapy, and guidance for sleep, light exposure, relationships, and daily routines—because that gives the neuroplastic window something healthy to grow around. (PMC)
From rapid change to durable change.
Ketamine’s antidepressant effects can arrive quickly, but after a single treatment they’re often time-limited—commonly measured in days, sometimes about a week—so the research and clinical protocols tend to use a series rather than a one-off session. (PMC+1)
A 90-day process creates enough runway to ground the therapies and daily practices that the data suggests. This time-frame allows us to establish an evidence-based cadence, track responses and side effects, adjust thoughtfully, and using each neuroplastic window to rehearse new behaviors and relational patterns. In real-world IV programs, response durability after an induction phase is only around 60% at eight weeks. That's exactly why consolidation and follow-through are built into Amphora's treatment rather than offered as an optional add-on. (ScienceDirect+2ScienceDirect+2)
What the research shows
Treatment-resistant depression
Ketamine has shown meaningful improvement in treatment-resistant depression, at times outperforming outcomes seen with electroconvulsive therapy, with a more favorable side effect profile.
At-home ketamine shows strong results for depression
A large 2024 real-world study found that structured, telehealth-supported at-home ketamine treatment led to significant reductions in depressive symptoms with a safety profile.
Anxiety, PTSD, and related conditions
Studies and real-world data suggest that ketamine can help reduce anxiety symptoms, soften hyperarousal, and create enough internal space to engage in trauma work.
Suicidal ideation
Meta-analyses show that ketamine can rapidly reduce suicidal thoughts—often within hours and lasting several days from a single treatment—creating a critical safety window to connect someone with ongoing support.
Subcutaneous ketamine for suicidal depression
A 2024 study found that subcutaneous ketamine was associated with significant reductions in suicidal thoughts and a meaningful functional improvement in those with severe depression.
At-home and telehealth-supported ketamine
Large real-world studies show that structured, telehealth-supported at-home ketamine can produce significant improvements in depression and anxiety, comparable to, even exceeding, traditional antidepressant outcomes.